GlaxoSmithKline (GSK ... controller of Germany’s Stada and owner of UK consumer products maker Thornton & Ross. Stada already announced earlier this month it would buy a small portfolio of ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

GSK is on track to achieve its guidance for 2024 ... But more broadly speaking, the company has pointed out earlier, “the annualisation of product launches and stocking impacts" are seen ...

The company has made significant progress in its pipeline, with 11 positive Phase III readouts and plans for five major new product approvals next year. GSK PLC (NYSE:GSK) successfully resolved ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

“Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, ” said Emma Walmsley, CEO. Guidance: GSK reaffirms ...

Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...